New Delhi, April 4 – India’s drug regulators are increasing their oversight of rapidly growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.This move comes as the...
The Drugs Controller of India has intensified regulatory oversight against the unauthorized sale and promotion of GLP-1-based weight loss drugs. This move comes amid growing concerns over the increasing availability of multiple generic versions of these drugs in the Indian market, through retail...
adverse effects
cardiologists
drugpromotiondrug sales
drugs controller of india
endocrinologists
glp-1 drugs
healthcare regulation
india
internal medicine specialists
medical supervision
pharmaceutical supply chain
prescription drugs
regulatory oversight
weight loss drugs
New Delhi, March 11 The apex drug regulator, CDSCO, has issued an advisory, directing that weight-loss drugs, specifically GLP-1 medications, must only be sold with a prescription from a registered medical practitioner.It cautioned pharmaceutical companies against "directly or indirectly"...